نتایج جستجو برای: Donepezil

تعداد نتایج: 1452  

Introduction: Donepezil (DON), an Acetylcholinesterase Inhibitor (AChEI), is widely used in the treatment of Alzheimer’s Disease (AD). The current study aimed at evaluating the effect of donepezil hydrochloride on pyramidal neuron response in CA1 region of a rat model of AD. Methods: In the current experimental study, adult male Wistar rats were randomly divided into four groups: Nucleus Basal...

Journal: :acta medica iranica 0
r. abolfazli s. ghazanshahi m. nazeman

alzheimer's disease is the most common degenerative disease of brain. nowadays, the most common treatment being used to slow down disease progression, include donepezil , rivastigmine and galantamine, which all of them act as inhibitors of acetyl cholinesterase. general purpose of our study was to show effects of treatment with donepezil and rivastigmine, as two drugs that commonly used for tre...

Journal: :Stroke 2003
Sandra Black Gustavo C Román David S Geldmacher Stephen Salloway Jane Hecker Alistair Burns Carlos Perdomo Dinesh Kumar Raymond Pratt

BACKGROUND AND PURPOSE Clinical observations suggest that patients with vascular dementia (VaD) may benefit from treatment with cholinesterase inhibitors. This study evaluated the efficacy and safety of donepezil for relieving symptoms of dementia in VaD. METHODS Patients (n=603; mean age, 73.9 years; 55.2% men) with probable (70.5%) or possible (29.5%) VaD, according to criteria of the Natio...

2017
Martin Knapp Derek King Renée Romeo Jessica Adams Ashley Baldwin Clive Ballard Sube Banerjee Robert Barber Peter Bentham Richard G Brown Alistair Burns Tom Dening David Findlay Clive Holmes Tony Johnson Robert Jones Cornelius Katona James Lindesay Ajay Macharouthu Ian McKeith Rupert McShane John T O'Brien Patrick P J Phillips Bart Sheehan Robert Howard

OBJECTIVE Most investigations of pharmacotherapy for treating Alzheimer's disease focus on patients with mild-to-moderate symptoms, with little evidence to guide clinical decisions when symptoms become severe. We examined whether continuing donepezil, or commencing memantine, is cost-effective for community-dwelling, moderate-to-severe Alzheimer's disease patients. METHODS Cost-effectiveness ...

2012
De-qiang Li Yu-ping Zhou Han Yang

AIM To evaluate the efficacy and safety of donepezil plus natural hirudin in patients with mild-to-moderate Alzheimer's Disease. METHODS In the 20-week, randomized, open-label and controlled study, 84 patients received either donepezil (5 mg/day for the first 4 weeks and 10 mg/day thereafter) or donepezil plus natural hirudin (3 g/day) treatment. Efficacy was reflected by the change of the to...

2016
Marwan Sabbagh SeolHeui Han SangYun Kim Hae-Ri Na Jae-Hong Lee Nagaendran Kandiah Kammant Phanthumchinda Chuthamanee Suthisisang Vorapun Senanarong Ming-Chyi Pai Diatri Narilastri Ajit M. Sowani Encarnita Ampil Amitabh Dash

BACKGROUND The 'Asia-Pacific Expert Panel (APEX) for donepezil 23 mg' met in November 2015 to review evidence for the recently approved high dose of donepezil and to provide recommendations to help physicians in Asia make informed clinical decisions about using donepezil 23 mg in patients with moderate-to-severe Alzheimer's disease (AD). SUMMARY In a global phase III study (study 326) in pati...

Journal: :Journal of the Neurological Sciences 2016
Etsuro Mori Manabu Ikeda Kenya Nakai Hideaki Miyagishi Masaki Nakagawa Kenji Kosaka

OBJECTIVE To investigate whether increasing plasma donepezil concentration further improves cognitive function and neuropsychiatric symptoms without compromising safety in patients with dementia with Lewy bodies (DLB). METHODS We analyzed data from a 12-week phase 3 trial of donepezil (5 and 10mg/day) in patients with DLB. The contribution of factors affecting plasma donepezil concentration w...

Journal: :British journal of clinical pharmacology 1998
S L Rogers L T Friedhoff

AIM The aim of this study was to characterize the pharmacokinetic and pharmacodynamic profile of donepezil HCl, a chemically distinct and specific acetylcholinesterase (AChE) inhibitor for the treatment of Alzheimer's disease, following administration of single oral doses. METHODS This was a double-blind, randomized, single-dose, placebo-controlled, sequential-group, ascending-dose study in h...

Journal: :The Journal of pharmacology and experimental therapeutics 2003
Yuki Takada Atsushi Yonezawa Toshiaki Kume Hiroshi Katsuki Shuji Kaneko Hachiro Sugimoto Akinori Akaike

Donepezil is a potent and selective acetylcholinesterase (AChE) inhibitor developed for the treatment of Alzheimer's disease. To elucidate whether donepezil shows neuroprotective action in addition to amelioration of cognitive deficits, we examined the effects of donepezil on glutamate-induced neurotoxicity using primary cultures of rat cortical neurons. A 10-min exposure of cultures to glutama...

2017
Yuta Yoshino Takaaki Mori Taku Yoshida Yasutaka Toyota Hideaki Shimizu Jun-ichi Iga Shusaku Nishitani Shu-ichi Ueno

Objective Donepezil is used to improve cognitive impairment of dementia with Lewy bodies (DLB). Visuo-spatial dysfunction is a well-known symptom of DLB. Non-verbal Raven's Colored Progressive Matrices (RCPM) were used to assess both visual perception and reasoning ability in DLB subjects treated with donepezil. Methods Twenty-one DLB patients (mean age, 78.7±4.5 years) were enrolled. RCPM as...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید